Keyphrases
Indonesia
100%
Chronic Pulmonary Aspergillosis
50%
Jakarta
48%
Aspergillus
38%
COVID-19 Patients
23%
Pulmonary Tuberculosis
18%
Voriconazole
18%
COVID-19
17%
Aspergillus Spp
17%
Tuberculosis Patients
16%
Post-tuberculosis
14%
Inhaler
13%
Clinical Characteristics
13%
Candidemia
12%
Aspergillus IgG
11%
Pneumocystis Jirovecii
11%
Candida Albicans (C. albicans)
10%
Antifungal Susceptibility
10%
Candida Krusei
10%
Quality of Life
9%
Galactomannan
9%
Fungal Infection
9%
Fluconazole
9%
Intensive Care Unit Patients
9%
Invasive Pulmonary Aspergillosis
9%
Chronic Obstructive Pulmonary Disease Patient
9%
Western Blot
9%
Bronchoalveolar Lavage
9%
Nave
9%
Intensive Care Unit
9%
Bronchoscopy
9%
Pulmonary Histoplasmosis
9%
Fungi
9%
Histoplasmosis
9%
Candida
8%
Particulate Matter 2.5 (PM2.5)
8%
Amphotericin B
8%
Significant Relationship
7%
Pulmonary mucormycosis
7%
Aspergillus Galactomannan
7%
Lung Cancer
7%
Indonesian
7%
Aspergillus Flavus
6%
Talaromyces
6%
Aspergillus Fumigatus
6%
Fungal Diseases
6%
Fungal Keratitis
6%
Krusei
6%
Sabouraud Dextrose Agar
6%
Clinical Features
6%
Pharmacology, Toxicology and Pharmaceutical Science
Aspergillus
46%
Lung Aspergillosis
37%
Diseases
18%
Candida Albicans
17%
Candida
17%
Chronic Obstructive Lung Disease
15%
Mycosis
13%
Cross-Sectional Study
12%
Lung Tuberculosis
12%
Candidemia
11%
Galactomannan
11%
Pichia kudriavzevii
10%
Fluconazole
10%
Lung Mycosis
10%
SARS Coronavirus
9%
Invasive Aspergillosis
9%
Prevalence
8%
Infection
8%
Respiratory Tract Disease
7%
Amphotericin B
7%
HIV
7%
Agar
7%
Talaromyces
7%
Histoplasma
6%
Klebsiella pneumoniae
6%
Histoplasmosis
6%
Enzyme-Linked Immunosorbent Assay
6%
Aspergillus flavus
6%
Lung Cancer
6%
IC50
5%
Brain Concussion
5%
Antifungal Activity
5%
Comorbidity
5%
Candida Tropicalis
5%
Side Effect
5%
Medicine and Dentistry
COVID-19
22%
Chronic Pulmonary Aspergillosis
19%
Lung Tuberculosis
13%
Aspergillus
12%
Intensive Care Unit
11%
Lung Lavage
9%
Bronchoscopy
9%
Diseases
8%
Fungal Pneumonia
8%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Human Immunodeficiency Virus
6%
Cross Sectional Study
6%
Pneumocystis Pneumonia
5%
Histoplasmosis
5%
Pneumocystis Jirovecii
5%